Launching the FIRST and ONLY
Continuous Glucose Monitor
(“CGM”) for Diabetic Companion
Animals
Singapore, SG -- June 8, 2021 --
InvestorsHub NewsWire -- ALR Technologies SG Pte. Ltd. (“ALRT”
or the “Company”) (OTCQB:
ALRT), the diabetes management company, today announces the
establishment of the ALRT Animal Health Division, a new business
division which will introduce the world’s FIRST and ONLY CGM for
diabetic companion animals.
The
revolutionary animal health solution is called
the GluCurve Pet CGM and will
be ready for the marketplace in 2022. It is powered by an adapted
ALRT Diabetes Solution platform with Insulin Dose Calculator for
companion animals. The GluCurve Pet
CGM will be sold to veterinarians throughout the
U.S. initially, with global distribution to
follow.
Currently, veterinarians perform a
“blood glucose curve” to determine the appropriate insulin dosage,
effectiveness of the therapy prescribed, and the frequency of
administration for diabetic animals. This process requires
veterinarians to draw blood from the pet every two hours during the
12-hour visit. The blood samples are tested in a blood glucose
meter and the data is manually plotted onto a graph to create a
“blood glucose curve”. This process is time consuming, expensive
for pet owners and financially unfavorable for veterinarians. More
importantly, it often yields inaccurate or unusable results due to
the stress caused on the pet being in the clinic for an extended
period and repeatedly having its blood
drawn.
The GluCurve Pet
CGM addresses an unmet need in diabetes care for
companion animals. It will eliminate the stress experienced by both
the diabetic pets and clinical staff in generating “blood glucose
curves”. It is easy to use, cost effective to pet owners and
financially favorable to
veterinarians.
The GluCurve Pet
CGM can be applied in minute and allows for the
pet to be promptly sent home where the CGM will automatically take
blood glucose readings every 5 minutes for up to 14 days. The CGM
will accumulate 288 daily datapoints which will be transmitted via
Bluetooth to the pet owner’s smart device and synchronized with the
ALRT portal to generate analytical reports for veterinarians.
The GluCurve Pet CGMprovides
accurate blood glucose data of the pets, allowing the veterinarian
to accurately prescribe insulin dosages and monitors their blood
sugar.
“The GluCurve Pet
CGM offers the effortless, accurate, affordable
and empowering solution which veterinarians are looking for as
reported by SmartPharma LLC, a pharmaceutical market research firm,
which conducted an extensive market research study with a large
number of veterinarians across the U.S.” said Joe Stern, Head of
ALRT Animal Health. “97% of veterinarians surveyed indicated they
would use the GluCurve Pet CGM. The
goal is for the GluCurve Pet
CGM to replace “blood glucose curves” currently
done by veterinarians using blood glucose meters and test
strips.”
Sidney Chan, Chairman and CEO of
ALRT went on to say, “There is an estimated 1,000,000 cats and dogs
receiving insulin for treatment of diabetes in the U.S., and
4,500,000 globally. We see the pet diabetes sector as a highly
profitable market for ALRT that will bring tremendous value to
shareholders in the near term while also providing better care for
diabetic pets, a more affordable solution for pet owners and better
tools for veterinarians and their
staff.”
Joe Stern concludes, “The market
research also indicated that veterinarians on average will use
the GluCurve Pet CGM three or
more times per year for pets under their care. Based on the
estimated diabetic pet population, that equates to the potential
annual use of more than 3 million GluCurve Pet
CGM in America and 13.5 million worldwide. Our
team has received enthusiastic responses from pharmaceutical
companies that provide insulin for companion animals and all the
major distributors in animal health products. We look forward to
sharing more updates with our customers, partners and investors in
the near future.”
About ALR Technologies SG Pte.
Ltd
ALR Technologies SG Pte. Ltd. is a
medical device company that developed the ALRT Diabetes Solution, a
comprehensive approach to diabetes care that includes: an
FDA-cleared and HIPAA compliant diabetes management system that
collects data directly from blood glucose meters and continuous
glucose monitoring devices; a patent pending Predictive A1C
algorithm to track treatment success between lab reports and an
FDA-cleared Insulin Dosing Adjustment program. ALRT also offers an
algorithm to provide prescribers support for timely non-insulin
medication advancements. The overall goal is to optimize diabetes
drug therapies to drive improved patient outcomes. The program
tracks performance of all clinical activities to ensure best
practices are followed. The ALRT Diabetes Solution gives providers
a platform for remote diabetes care, helping to minimize patient
exposure to potential infections in clinical settings. Currently,
the Company is focused on diabetes and will expand its services to
cover other chronic diseases anchored on verifiable
data.
In addition, the ALRT Animal Health
Division is dedicated to ethically improving the quality of life
for animals by utilizing technology to solve gaps in medical care
for veterinarians worldwide. The Company has identified
an unmet need in diabetes care and has developed a solution to
assist veterinarians in determining the effectiveness of insulin
and helping to identify the appropriate dose and frequency of
administration for companion animals. Thus delivering the same
optimization of diabetic drug therapies to pets as to
humans.
ALR Technologies SG Pte. Ltd. is a
wholly owned subsidiary of ALR Technologies Inc. On June 1, 2021
ALR Technologies Inc. announced its intention to migrate to
Singapore More information about ALR Technologies Inc. can be found
at www.alrt.com.
More information about ALR Technologies SG Pte. Ltd. can be found
at https://sg.alrt.com.
Contact: Ken Robulak (U.S.): +1
(727) 736-3838, Anthony Ngai (Singapore): +65 3129 2924
email: info@alrt.com
This
release contains certain "forward-looking statements" relating to
ALR Technologies' business, and these statements reflect the
current views of ALR Technologies with respect to future events and
are subject to certain risks, uncertainties, and assumptions. When
used, the words "estimate", "expect", "anticipate", "believe",
“will” and similar expressions are intended to identify such
forward-looking statements. There are many factors that could cause
the actual results, performance, or achievements of ALR
Technologies and its products to be materially different from any
future results, performances or achievements that may be expressed
or implied by such forward-looking statements. Further management
discussions of risks and uncertainties can be found in the
Company's quarterly filings with the Securities Exchange
Commission.
ALR Technologies (QB) (USOTC:ALRT)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
ALR Technologies (QB) (USOTC:ALRT)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024